| Date Filed | Type | Description |
| 07/03/2023 |
3
| Sapir Alex (See Remarks) has filed a Form 3 on Fulcrum Therapeutics, Inc. |
| 05/19/2023 |
4
| Sapir Alex (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc|
Txns:
| Exercised 3,750 restricted stock units
@ $0 |
|
| 05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/05/2020 |
4
| Sapir Alex (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc|
Txns:
| Granted 4,909 options to buy
@ $4.86, valued at
$23.9k
|
|
| 02/14/2020 |
4
| Sapir Alex (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc|
Txns:
| Granted 32,000 options to buy
@ $5.19, valued at
$166.1k
|
|
| 02/14/2020 |
3
| Sapir Alex (Director) has filed a Form 3 on PhaseBio Pharmaceuticals Inc |
| 08/15/2018 |
4
| Sapir Alex (President & CEO) has filed a Form 4 on Dova Pharmaceuticals, Inc.|
Txns:
| Bought 21,700 shares
@ $22.83, valued at
$495.4k
|
|
| 12/27/2017 |
4
| Sapir Alex (President & CEO) has filed a Form 4 on Dova Pharmaceuticals, Inc.|
Txns:
| Exercised 26,809 options to buy
@ $3.73, valued at
$100k
|
|
| 07/07/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 06/28/2017 |
3
| Form 3 - Initial statement of beneficial ownership of securities |